News Quantified

EIGR – eiger biopharmaceuticals, inc. (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Sentynl Therapeutics Announces Global Acquisition of Zokinvy® (Lonafarnib) for Treatment of Hutchinson-Gilford Progeria Syndrome from Eiger BioPharmaceuticals [Yahoo! Finance]

Sentynl Therapeutics Announces Global Acquisition of Zokinvy® (Lonafarnib) for Treatment of Hutchinson-Gilford Progeria Syndrome from Eiger BioPharmaceuticals

Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.

BRNS, UPC and KWE among mid-day movers [Seeking Alpha]

Eiger BioPharmaceuticals Files for Voluntary Chapter 11 Protection [Yahoo! Finance]

Form 10-K Eiger BioPharmaceuticals For: Dec 31

Form 8-K Eiger BioPharmaceuticals For: Apr 01

Form NT 10-K Eiger BioPharmaceuticals For: Dec 31

Form S-8 POS Eiger BioPharmaceuticals

Form S-8 POS Eiger BioPharmaceuticals

Top News Gainers

12/20 Form S-3 Eiger BioPharmaceuticals 9.1%

1/13 Eiger Biopharmaceuticals Inc (NASDAQ: EIGR) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $16.00 price target on the stock. 6.6%

3/13 Q4/2019 12/31/2019 EPS -0.690 ZacksConsensus -0.800 ActVsEst 0.110 - Beat 5.5%

3/23 Eiger BioPharmaceuticals Completes Submission of New Drug Application to FDA for Lonafarnib for Treatment of Progeria and Progeroid Laminopathies 5.4%

6/17 Eiger Announces Breakthrough Therapy Designation Granted by FDA for Avexitide for Treatment of Post-Bariatric Hypoglycemia (PBH) 4.8%

11/18 Form SC 13D/A Eiger BioPharmaceuticals Filed by: Vivo Ventures VI, LLC 3.6%

6/14 Form SC 13G Eiger BioPharmaceuticals Filed by: Broadfin Capital, LLC 3.6%

7/9 Eiger Biopharmaceuticals Inc (NASDAQ: EIGR) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $11.00 price target on the stock. 3.2%

2/14 Form SC 13G/A Eiger BioPharmaceuticals Filed by: RA CAPITAL MANAGEMENT, L.P. 3.2%

7/16 Eiger Biopharmaceuticals Inc (NASDAQ: EIGR) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $12.00 price target on the stock. 2.2%

Top News Decliners

3/13 Form 4 Eiger BioPharmaceuticals For: Mar 12 Filed by: Patton Stephana Eilene -16.9%

4/3 Eiger Biopharmaceuticals Inc (NASDAQ: EIGR) had its "buy" rating re-affirmed by analysts at Wedbush. They now have a $33.00 price target on the stock. -13.9%

4/1 Form 8-K Eiger BioPharmaceuticals For: Apr 01 -13.0%

4/30 Eiger BioPharmaceuticals Announces First COVID-19 Patients Dosed with Peginterferon Lambda -8.7%

3/17 Form 4 Eiger BioPharmaceuticals For: Mar 16 Filed by: Glenn Jeffrey S -8.4%

4/27 Eiger BioPharmaceuticals Announces EMA Validation of Lonafarnib MAA for Treatment of Progeria and Progeroid Laminopathies -8.0%

8/5 Eiger BioPharmaceuticals to Participate in Investor Conferences in August -6.4%

8/12 Eiger Biopharmaceuticals Inc (NASDAQ: EIGR) had its "buy" rating re-affirmed by analysts at LADENBURG THALM/SH SH. They now have a $28.00 price target on the stock. -5.9%

3/5 Eiger Biopharmaceuticals Inc (NASDAQ: EIGR) was downgraded by analysts at ValuEngine from a "strong-buy" rating to a "buy" rating. -5.5%

3/27 Eiger Biopharmaceuticals Inc (NASDAQ: EIGR) had its "outperform" rating re-affirmed by analysts at Wedbush. -4.6%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day